Abstract: The present disclosure relates to methods of treating a range of diseases or conditions. The methods involve administration of a superoxide dismutase mimetic.

Abstract: The present invention provides a pharmaceutical composition for preventing or treating inflammatory diseases, containing, as an active ingredient, stem cells overexpressing SOD3. The present inventor has ascertained that mesenchymal stem cells (MSCs) overexpressing SOD3 have a stronger antioxidant activity and immune regulatory function than normal MSCs, and thus the MSCs overexpressing SOD3 can be an effective treatment agent for inflammatory diseases, autoimmune diseases, organ transplant rejection and the like.

Abstract: Compositions and methods for the treatment of pruritic ani and anal fissures are described. The compositions include one or more of Calamine (USP) or zinc oxide (ZnO), aluminum hydroxide (Al(OH)3) glycerin, and menthol (or any compound which activates the menthol receptor (TRPM8)). The composition does not contain (or contains a limited amount, such as less than 10%) of a hydrocarbon-based pharmaceutical carrier such as petroleum jelly, white petrolatum, mineral oil, hard paraffin, soft paraffin, microcrystalline wax, or ceresine. Methods of treating pruritic ani and anal fissures by topical application(s) of the compositions to affected perianal or anal epidermis are also described.

Abstract: The present invention provides an oligonucleotide probe for single nucleotide polymorphism detection to be used for a target nucleic acid where a single nucleotide polymorphism is present, the oligonucleotide probe comprising a reporter region, an anchor region, and a linker region. The reporter region comprises: an oligonucleotide consisting of a sequence perfectly matching when a nucleotide of the single nucleotide polymorphism is a first nucleotide, and mismatching when the nucleotide of the single nucleotide polymorphism is a nucleotide other than the first nucleotide; and a fluorescent dye quenching when the reporter region hybridize to the target nucleic acid.

Abstract: Compositions and methods of enhancing the potency and efficacy of adoptive cell therapy using integrin-ligand stabilizers, wherein the integrin is selected from the group consisting of ?4?1, ?5?1, ?4?7, ?v?3 and ?L?2, and contacting the effector cells ex vivo with agonists or stabilizers having the general Formula (I); methods of treating integrin-expressing cells with such stabilizers to enhance tumor infiltration; and therapeutic methods comprising administering stabilizer or agonist-treated cells to a mammal requiring treatment of solid tumors, hematologic cancers.

Abstract: An organometallic compound represented by Formula 1: wherein, in Formula 1, groups and variables are the same as described in the specification.

Abstract: An organometallic compound represented by Formula 1: wherein, in Formula 1, R1 to R12 and R16 are the same as described in the specification.

Abstract: Disclosed is a family of corroles for its use in the treatment of an infection by human herpesvirus, especially in the treatment of an infection by human cytomegalovirus.

Abstract: The present disclosure relates platinum(IV) and texaphyrin linked conjugates and compositions comprising a texaphyrin and a platinum(IV) agent. The present disclosure also provides pharmaceutical compositions of the conjugates and compositions. Also, provided herein are methods of using the instant compounds in the treatment of cancer such as a platinum resistant cancer.

Abstract: Compounds may be administered to prevent or rescue organ injury following exposure to alkylating agents, such as sulfur mustards. The compounds may be substituted metalloporphyrins.

Abstract: The present invention relates to a method for selecting a target region of interest (ROI) in a target nucleic acid molecule using a nucleic acid probe comprising a 3? sequence capable of hybridising to a target nucleic acid molecule and acting as a primer for the production of a complement of the target ROI (i.e. by target templated extension of the primer), and a sequence capable of templating the circularisation and ligation of the extended probe comprising the reverse complement of the target ROI and a portion of the probe. The circularised molecule thus obtained contains the reverse complement of the target ROI and may be subjected to further analysis and/or amplification etc. The probe may be provided as an oligonucleotide comprising a stem-loop structure or as a partially double-stranded construct and comprises a single-stranded 3? end region containing the target-binding site.

Abstract: The present disclosure relates to methods and products for reducing the viability of microorganisms, and to methods and products for preventing and/or treating microorganism infections. Certain embodiments of the present disclosure provide a method for reducing viability of a microorganism. The method comprises exposing the microorganism to an effective amount of an iron chelator and subsequently exposing the microorganism to an effective amount of a non-iron porphyrin, thereby reducing the viability of the microorganism.

Abstract: The invention provides a method of karyotyping (for example for the detection of trisomy) a target cell to detect chromosomal imbalance therein, the method comprising: (a) interrogating closely adjacent biallelic SNPs across the chromosome of the target cell (b) comparing the result at (a) with the SNP haplotype of paternal and maternal chromosomes to assemble a notional haplotype of target cell chromosomes of paternal origin and of maternal origin (c) assessing the notional SNP haplotype of target cell chromosomes of paternal origin and of maternal origin to detect aneuploidy of the chromosome in the target cell. Also provided are related computer-implemented embodiments and systems.

Abstract: A conjugate of formula (A): where Y is selected from a single bond, and a group of formulae A1 or A2: where N shows where the group binds to the N10 of the PBD moiety; RL1 and RL2 are independently selected from H and methyl, or together with the carbon atom to which they are bound form a cyclopropylene group; CBA represents a cell binding agent; Q is independently selected from O, S and NH; R11 is either H, or R or, where Q is O, SO3M, where M is a metal cation.

Abstract: The present disclosure describes the thermodynamic design and concentrations necessary to design probe compositions with desired optimal specificity that enable enrichment, detection, quantitation, purification, imaging, and amplification of rare-allele-bearing species of nucleic acids (prevalence <1%) in a large stoichiometric excess of a dominant-allele-bearing species (wildtype). Being an enzyme-free and homogeneous nucleic acid enrichment composition, this technology is broadly compatible with nearly all nucleic acid-based biotechnology, including plate reader and fluorimeter readout of nucleic acids, microarrays, PCR and other enzymatic amplification reactions, fluorescence barcoding, nanoparticle-based purification and quantitation, and in situ hybridization imaging technologies.

Abstract: Large scale (bulk) compositions comprising high-purity stannsoporfin are disclosed, as well as methods of synthesizing such compositions.

Abstract: The present invention provides a method for detecting an analyte in a sample, said method comprising a) contacting said sample with a set of proximity probes comprising at least first and second proximity probes, which probes each comprise an analyte-binding domain capable of binding directly or indirectly to said analyte and a nucleic acid domain, such that the proximity probes can simultaneously bind, directly or indirectly, to the analyte, wherein i) the nucleic acid domains of said first and second proximity probes comprise regions capable of mediating an interaction involving said domains when under permissive conditions; and ii) the nucleic acid domain of one of said first and second probes comprises an HCR initiator region comprised within a metastable secondary structure such that it is unable to initiate an HCR reaction until released from said metastable secondary structure; b) introducing permissive conditions to allow the nucleic acid domains of said first and second probes to interact with each o

Abstract: A treatment method is disclosed capable of reducing the burden on a patient and enhancing the effect of killing tumor cells. A treatment method for killing a tumor cell, the method including inserting a catheter into a main artery of an organ having the tumor cell, administering an antibody-photosensitive substance into a vein before the inserting of the catheter, inserting an optical fiber into the catheter, reducing an influence of blood in the artery on a near-infrared ray, irradiating at least one of a tumor, the vicinity of the tumor, or a regional lymph node with a first near-infrared ray by the optical fiber, and irradiating an antibody-photosensitive substance bound to a tumor cell membrane in the tumor cell with a second near-infrared ray having a shorter wavelength than that of the first near-infrared ray.

Abstract: The present application relates to a phthalocyanine, to a method for preparing the phthalocyanine, and to an object coated or impregnated with the phthalocyanine. The present application also relates to a method for providing reactive oxygen species, and to a method for disinfecting materials, including providing reactive oxygen species to the material to disinfect the material by oxidative action.

Abstract: The present invention relates to a pharmaceutical topical gel solution that contains 5-aminolevulinic acid (5-ALA) and an aqueous low viscous gel matrix. This invention also relates to a pharmaceutical preparation containing this composition. The formulation of this type can be used in photodynamic therapy as well as in the photodynamic detection of abnormally proliferating cells.

Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.

Abstract: The present disclosure is in relation to the field of nanotechnology and cancer therapeutics. In particular, the present disclosure relates to platinum based compounds comprising platinum moiety, linker moiety and lipid moiety and corresponding nanoparticles thereof. The disclosure further relates to synthesis of said platinum based compounds, nanoparticles and compositions comprising said platinum based compounds/nanoparticles. The disclosure also relates to methods of managing cancer by employing aforesaid carbene compounds, platinum based compounds, nanoparticles and compositions thereof.

Abstract: A compound and method for detecting hypoxic cells and tissue are provided. The compound includes a probe selected from the group consisting of a hypoxia sensitive 2-nitroimidazole containing fluorescence imaging probe, a hypoxia sensitive reversible ON-OFF fluorescence imaging probe, a hypoxia sensitive azo-based fluorescence imaging probe, and combinations thereof. The method includes contacting the cells or tissue with the probe of any one of claims 1-13 and detecting fluorescent intensity of the cell or tissue, wherein increased fluorescent intensity indicates that the cells or tissue is hypoxic. Also provided are a method of synthesizing the compound and a method for synthesizing a therapeutic agent including the compound.

Abstract: A composition and method for supplementing food, nutrition, and diet systems with omega-6 to omega-3 balanced oils comprising a synergistic blend of at least two oils. The composition further comprises a synergistic blend of long chain omega-3 oil as a means to further increase the nutritional value. The composition provides an effective increase in therapeutic and pharmacological properties in nutrition and diet systems.

Abstract: Use of (pyrophosphato)platinum(II) or (pyrophosphato)platinum(IV) complexes (“phosphaplatin compounds”), especially (R,R)-1,2-cyclohexanediamine-(dihydrogen pyrophosphato)platinum(II) (or “PT-112”), as therapeutic agents for treatment of bone and blood cancers, or cancers that metastasize to bones, and methods thereof, are disclosed.

Abstract: Large scale (bulk) compositions comprising high-purity stannsoporfin are disclosed, as well as methods of synthesizing such compositions.

Abstract: Aspects of the present disclosure relate to compounds which have enhanced oral bioavailability. A transition metal complex includes a transition metal coordinated by a macrocycle comprising the pentaaza 15-membered macrocyclic ring corresponding to Formula A and two axial ligands having the formula —OC(O)X1. each of the two axial ligands has the formula —OC(?O)X1 wherein each X1 is independently substituted or unsubstituted phenyl or —C(—X2)(—X3)(—X4); each X2 is independently substituted or unsubstituted phenyl, or substituted or unsubstituted alkyl; each X3 is independently hydrogen, hydroxyl, alkyl, amino, —X5C(?O)R13 where X5 is NH or O, and R13 is C1-C18 alkyl, substituted or unsubstituted aryl or C1-C18 aralkyl, or —OR14, where R14 is C1-C18 alkyl, substituted or unsubstituted aryl or C1-C18 aralkyl, or together with X4 is (?O); and each X4 is independently hydrogen or together with X3 is (?O).

Abstract: A hand sanitizing composition and a method of manufacture, wherein the composition includes a solvent from about 78% to about 96% by weight sufficient to operate as a carrier and solvent. The composition includes tetrasodium EDTA and/or Sodium Citrate from about 0.01% to about 1% by weight to operate as a buffer, stabilizer and chelating agent. The composition includes a humectant selected from the group of humectants consisting of: Cetyl Alcohol, Ceteryl Alcohol, and Steryl Alchohol from about 1.5% to about 5.5% by weight to emulsify, thicken and lubricate. The composition includes an emollient from about 0.1% to about 3.2% by weight and an antioxidant vitamin from about 0.01% to about 1% by weight. The composition includes a soothing agent in a therapeutically significant amount and a conditioner.

Abstract: A radiation detection system and method for a neutron capture therapy system, which may increase the accuracy of neutron beam irradiation dose of the neutron capture therapy system and find out a fault position in time. The neutron capture therapy system includes a charged particle beam, a charged particle beam inlet allowing the charged particle beam to pass through, a neutron beam generating unit which may generate a neutron beam after a nuclear reaction occurs between the neutron beam generating unit and the charged particle beam, a beam shaping assembly for adjusting the flux and the quality of the neutron beam generated by the neutron beam generating unit, and a beam outlet adjacent to the beam shaping assembly, the radiation detection system includes a radiation detection device for real-time detection of ? rays instantly emitted under neutron beam irradiation.

Abstract: A process of providing an antibacterial coating to the surface of an article including the steps of applying a layer of an antibacterial precursor layer to the surface of an article to which an antibacterial coating is to be applied, wherein said antibacterial precursor layer is a precursor from which the coating is to be formed; and directing a neutral molecular hydrogen flux from a neutral molecular hydrogen flux emission source towards the surface of the article. Upon impact of neutral hydrogen molecules on molecules at or on the surface of an article, the bonds of the antibacterial precursor layer are selectively ruptured, and wherein the selectively ruptured bonds cross-link with themselves or with other chemical moieties at said surface or a combination thereof, resulting an antibacterial coating being formed on the surface of the article.

Abstract: The present disclosure relates to methods of treating a range of diseases or conditions. The methods involve administration of a superoxide dismutase mimetic.

Abstract: The present invention relates to carboxamide halogenated porphyrin derivatives, in particular bacteriochlorin or chlorin, of formula (I) use of the same or a pharmaceutically acceptable salt thereof in photodynamic therapy, where the derivatives are able to detect and exhibit the presence of hyperproliferative disorders and, in the presence of an adequate lighting, to treat the same. The present invention also describes a pharmaceutical composition having the carboxamide halogenated porphyrin derivatives, in particular bacteria-chlorin or chlorin, of Formula (I) or a pharmaceutically acceptable salt thereof, for the treatment of cancer and/or microbial and/or viral infections, in humans or animals.

Abstract: The present disclosure relates platinum(IV) and texaphyrin linked conjugates and compositions comprising a texaphyrin and a platinum(IV) agent. The present disclosure also provides pharmaceutical compositions of the conjugates and compositions. Also, provided herein are methods of using the instant compounds in the treatment of cancer such as a platinum resistant cancer.

Abstract: Disclosed is an arene ruthenium complex with R1, R2, R3, and piperidine as main ligands, preparation method and utilization thereof. R1, R2, R3 are selected from —H, —Cl, —F, —Br, —I, —CF3, —NO2, —OCH3, —OH, —COOH, —CH3, —N(CH3)2, —C2H2, —SO2CH3, alkane with 1 to 6 carbon atoms, substituted alkyl with 1 to 6 carbon atoms, phenyl, substituted phenyl, pyridyl, substituted pyridyl, furyl, substituted furyl, pyrrolyl, substituted pyrrolyl, thiazyl or substituted thiazyl group respectively. The substituted groups in the substituted phenyl, substituted pyridyl, substituted furyl, substituted thiazyl and substituted pyrrolyl are selected from hydroxyl, nitro, halogen, amido, carboxyl, cyano, thiol or naphthene group with 3 to 8 carbon atoms, SO3H, alkane with 1 to 6 carbon atoms, alkenyl with 2 to 6 carbon atoms, alkyne with 2 to 6 carbon atoms, C1-C6 hydroxyalkane, C1-C6 aminoalkane, CO2R?, CONR?R?, COR?, SO2R?R?, C1-C6 alkoxyl, C1-C6 alkyl thiol, —N?NR?, NR?R? or C1-C6 trifloroalkyl.

Abstract: A method for destroying cells and/or microorganisms in an organism includes the following steps: (a) administering to the organism a composition including a photodynamic compound containing at least one transition metal; and (b) irradiating the photodynamic compound in the organism with electromagnetic radiation, wherein the electromagnetic radiation includes ionizing radiation and is effective to activate the photodynamic compound to destroy at least one of the cells and the microorganisms in the organism. The ionizing radiation is preferably X-rays and/or gamma rays. The non-ionizing radiation is preferably light in the range from 600-950 nm.

Abstract: The use of cobalt porphyrins for the manufacture of an agent for mobilizing bone marrow cells to peripheral blood, preferably used to treat congenital neutropenia, for the treatment and prevention of neutropenia caused by chemotherapy, radiotherapy and pharmacologically-induced neutropenia, for the treatment of acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndromes, and to increase the amount of circulating hematopoietic stem cells in peripheral blood for subsequent isolation in the process of apheresis and allogeneic or autologous transplantation.

Abstract: This invention is directed to derivatives of piperidine-2,6-dione, or their organic or inorganic salts thereof, a methods of synthesis of these derivatives, and their application as active pharmaceutical ingridient as inhibitors of TNF? releasing in cells, the derivative of piperidine-2,6-dione being of the general formula (I): wherein n represents 1, 2, 3, 4, 5 or 6; R1 represents from one to four of the same or different substituents selected from F, Cl, Br, C1-4 alkyl, OH, OC1-4 alkyl, NO2, NHC(O)C1-4 alkyl, NH2, NH(C1-4 alkyl), N(C1-4 alkyl)2; R2 represents OR3, NR3R4, N(R3)COR4, O2CR5; R3 and R4 represent independently and at each occurrence H or C1-4 alkyl; R5 represents CHR6NR7R8, CHR6NR9C(O)CHR10NR7R8, a heterocycle W or CHR6NR9C(O)W; R6, R9, R10 represent independently and at each occurrence H, or C1-4 alkyl; R7 and R8 represent independently and at each occurrence H, C1-4 alkyl, or R7 and R8 taken together represent 1,3-propylene, 1,4-butylene, 1,5-pentylene , or 1,6-hexylene; W represents four-

Abstract: Provided herein are photosensitizer compounds for use in a variety of clinical, industrial, and research applications. In particular, provided are deep eutectic solvents and natural deep eutectic solvents for use in killing of bacteria.

Abstract: A method of treating pruritus (itching) in a subject in need thereof is carried out by administering the subject an active agent in a treatment effective amount, wherein the active agent is a superoxide dismuate (SOD) mimetic. The SOD mimetic can be a complex of a metal (e.g., manganese) and an organic ligand, with suitable organic ligands including porphyrins, polyamines, salens, nitroxides, and fullerenes. Compositions for carrying out such methods are also described.

Abstract: The use of cobalt porphyrins for the manufacture of an agent for mobilizing bone marrow cells to peripheral blood, preferably used to treat congenital neutropenia, for the treatment and prevention of neutropenia caused by chemotherapy, radiotherapy and pharmacologically-induced neutropenia, for the treatment of acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndromes, and to increase the amount of circulating hematopoietic stem cells in peripheral blood for subsequent isolation in the process of apheresis and allogeneic or autologous transplantation.

Abstract: Disclosed herein are organometallic complexes and methods of using the same in detecting double stranded DNA or RNA, selectively over single stranded DNA or RNA.

Abstract: A composition including a metalloinsertor conjugate that specifically targets mismatch repair (MMR)-deficient cells includes a complex represented by Formula I. Mm+(L1)(L2)(L3)(L4)(L5)??Formula I Selective cytotoxicity may be induced in MMR-deficient cells upon uptake of the metalloinsertor conjugate. Metalloinsertor complexes conjugated with platinum (Pt) may allow for more specific targeting of platinum anticancer agents.

Abstract: The present invention generally relates to the field of medical nutrition. For example, the present invention provides a composition that can be used to treat, prevent and/or reverse muscle atrophy related to immobilization and its consequences. One embodiment of the present invention concerns a composition comprising a leucine and antioxidants that can be used in accelerating muscle recovery after muscle atrophy.

Abstract: Methods and kits for treating oral mucositis are disclosed. The treatment comprises administering to a patient in need thereof a Reactive Oxygen Species scavenger in a pharmaceutically acceptable formulation.

Abstract: The present invention relates to using a versatile synthetic approach to generate a new class of ester, amido, or carbamate prodrugs of highly potent, but systemically too toxic, platinum-acridine anticancer agents. The new hybrids contain a hydroxyl group, which has been masked with a cleavable lipophilic acyl moiety. Both butanoic (butyric) and bulkier 2-propanepentanoic (valproic) esters were introduced to these compounds. The goal of this design was to improve the drug-like properties of the pharmacophore (e. g., log D) without compromising its DNA-mediated cell kill potential. Two distinct pathways by which the target compounds undergo effective ester hydrolysis, the proposed activating step, have been confirmed: platinum-mediated, self-immolative ester cleavage in a low-chloride environment (LC-ESMS, NMR spectroscopy) and enzymatic cleavage by human carboxylesterase-2 (hCES-2) (LC-ESMS).

Abstract: The object of the present invention is to elucidate the resistance mechanism in infections that show resistance to ALA-PDT that uses a single ALA, and to provide a novel treatment method against these infections. The present invention provides a pharmaceutical composition for promoting protoporphyrin IX production in ALA-PDT for treating infection, characterized in that it comprises a substance that promotes the conversion from coproporphyrinogen III to protoporphyrin IX.

Abstract: A new self-magnetic metal-salen complex compound and its derivatives are provided. The present invention is a metal-salen complex compound including any one of the following compounds.

Abstract: This invention relates to photodynamic therapy (PDT) of vulnerable plaque using two pluralities of nanoparticles, one plurality comprising a PDT agent that is sensitive to blue-green light wherein the nanoparticles are capable of penetrating only into the fibrous cap of the vulnerable plaque and one plurality comprising a PDT agent that is sensitive to red light wherein the nanoparticles are capable of penetrating into the core of the vulnerable plaque.

Abstract: Wounds in the eye following surgery or injury are sealed by soaking the area with a riboflavin solution containing iodide ion and irradiating the wound area with UVA radiation in a selected wavelength range for a selected time period to promote cross-linking of tissue between opposite surfaces of the wound or between the incised wound surfaces and a graft or implant.

Abstract: Antagonistic antibodies that specifically bind to and inhibit Class A Eph receptors are provided. Also provided are cytotoxic conjugates, pharmaceutical compositions and kits comprising these antibodies.